Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress-Reference-Cited by-同舟云学术

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Published:2020-05 Issue:8 Volume:31 Page:107669
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Nyquist Michael D.,Corella Alexandra,Coleman Ilsa,De Sarkar Navonil,Kaipainen Arja,Ha Gavin,Gulati Roman,Ang Lisa,Chatterjee Payel,Lucas Jared,Pritchard Colin,Risbridger Gail,Isaacs John,Montgomery Bruce,Morrissey Colm,Corey Eva,Nelson Peter S.

Funder

Foundation for the National Institutes of Health

Congressionally Directed Medical Research Programs

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference50 articles.

1. Genomic correlates of clinical outcome in advanced prostate cancer;Abida;Proc. Natl. Acad. Sci. USA,2019

2. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer;Annala;Cancer Discov.,2018

3. Platinum-based chemotherapy for variant castrate-resistant prostate cancer;Aparicio;Clin. Cancer Res.,2013

4. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling;Bluemn;Cancer Cell,2017

5. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer;Bohrer;Endocrinology,2010

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

2. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

3. Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines;2024-08-30

4. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients;European Urology Oncology;2024-08

5. Network pharmacology and experimental validation to explore the role and potential mechanism of Liuwei Dihuang Decoction in prostate cancer;BMC Complementary Medicine and Therapies;2024-07-26